Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesEndocrinologyBlue Cross NC FCS Therapy Coverage Update | OpenPa…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - North CarolinaPolicy N/A

    Familial Chylomicronemia Syndrome Therapy

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - North Carolina policy alerts

    Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity, site-of-care, and prior authorization requirements for use of olezarsen (Tryngolza) and plozasiran (Redemplo) as adjuncts to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS) for Blue Cross NC members.

    Policy Summary
    PayerBlue Cross Blue Shield - North Carolina
    PolicyFamilial Chylomicronemia Syndrome Therapy
    Policy CodePolicy N/A
    Change TypeAdded and revised coverage for Tryngolza and Redemplo
    Effective DateApr 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with medical record documentation confirming FCS diagnosis, baseline fasting TG values, and trial/failure of conventional therapy (and for olezarsen, trial/failure of plozasiran or documented intolerance).
    SourceLink
    POLICY UPDATE CHANGES

    Added olezarsen (Tryngolza) to policy for the treatment of adults with familial chylomicronemia syndrome, as an adjunct to diet to reduce triglycerides.

    For Tryngolza, added requirement for trial and failure of Redemplo (or intolerance/contraindication) and requirement for use of self-administered formulation unless criteria for supervised administration are met.

    Added associated dosing, maximum units, and HCPCS codes C9399, J3490, and J3590 to the FDA label reference table for Tryngolza and Redemplo.

    Removed requirement for medical record documentation for specialist requirement, concomitant use statement, and verification that secondary causes have been ruled out.

    Changed policy name from 'Plozasiran (Redemplo ® )' to 'Familial Chylomicronemia Syndrome Therapy'.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2restricted products listed
    365duration of approval (initial and continuation)
    ≥880baseline fasting TG threshold
    olezarsen:80mg/modosing per policy
    960/100max units (olezarsen/plozasiran)

    Coverage and Medical Necessity Criteria

    Site of Care

    Site-of-Care Medical Necessity Criteria for inpatient/outpatient administration:

    Inpatient or Outpatient Hospital Administration: 1. For inpatient administration: above medical necessity criteria are met AND the inpatient admission is NOT for the sole purpose of administering the injection or infusion; OR 2. For outpatient hospital administration: above medical necessity criteria are met AND ONE of the following is met: (a) history of a severe adverse event following the injection/infusion (e.g., anaphylaxis, seizure, thromboembolism, myocardial infarction, renal failure), OR (b) conditions that increase risk for severe adverse event (e.g., unstable renal function, cardiopulmonary conditions, unstable vascular access), OR (c) history of mild adverse events not managed with pre-medication, OR (d) inability to physically/cognitively adhere to the treatment schedule, OR (e) new to therapy (initial injection/infusion or <3 months since initial), OR (f) re-initiation of therapy as defined by policy (first injection after defined gaps), OR (g) requirement to change the restricted product formulation. If neither #1 nor #2 criteria are met, administration should occur in a home-based infusion or physician office setting (with or without supervision by a certified healthcare professional).

    The requested agent must not be received in combination with olezarsen (Tryngolza) or plozasiran (Redemplo). This is a required exclusion in the initial and continuation coverage criteria and medical record documentation should demonstrate that the member will not be co‑administered either restricted product.

    Injection or infusion administration in an inpatient setting solely for the purpose of administering the injection/infusion is not permitted. Inpatient administration is only allowed when the admission is for clinical reasons beyond drug administration and the member meets the policy's medical necessity criteria. If inpatient or outpatient hospital administration is requested, the applicable Site‑of‑Care Medical Necessity Criteria must be met; otherwise administration should occur in a home‑based infusion or physician office setting.

    Coding, Dosing, and Clinical Thresholds

    HCPCS codes listedHCPCS
    C9399Unclassified HCPCS code (listed in policy for olezarsen and plozasiran)
    J3490Unclassified drug, injectable, listed in policy for olezarsen and plozasiran
    J3590Unclassified biologics, listed in policy for olezarsen and plozasiran
    Baseline fasting triglycerides — diagnostic threshold
    ThresholdBaseline fasting triglycerides ≥880 mg/dL
    Occasions requiredMeasured on at least 3 separate occasions
    DocumentationMedical record documentation required for the baseline TG measurements

    Prior Authorization, Documentation, and Provider Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for olezarsen (Tryngolza) and plozasiran (Redemplo). Requests must meet the applicable initial or continuation criteria and dosing/maximum units must correspond to the HCPCS entries and maximum units listed in the policy.

    • Affected HCPCS: C9399, J3490, J3590
    • Maximum units: olezarsen = 960; plozasiran = 100
    Step Therapy

    Step-Therapy Requirement for Olezarsen

    For olezarsen (Tryngolza) only: a documented trial and inadequate response to plozasiran (Redemplo) OR documented intolerance, FDA-labeled contraindication, or hypersensitivity to plozasiran is required before approval.

    • Must document trial and inadequate response to plozasiran OR intolerance/contraindication/hypersensitivity to plozasiran

    Background and Condition Overview

    Familial chylomicronemia syndrome (FCS) is a rare genetic disorder that results in severe hypertriglyceridemia and an increased risk of recurrent acute pancreatitis. Management centers on strict dietary fat restriction and therapies that lower triglycerides. Targeted agents such as olezarsen (Tryngolza) and plozasiran (Redemplo) are approved as adjuncts to a low‑fat diet to reduce triglyceride levels in adults with confirmed FCS. Policy criteria require objective confirmation of FCS (genetic testing, NAFCS, or repeated fasting triglyceride measurements), documentation of baseline fasting triglycerides, and evidence of pancreatitis history or other qualifying features prior to initiating these agents.

    Definitions and Diagnostic Criteria

    Genetic confirmation — FCS diagnostic criteria
    DefinitionBi-allelic pathogenic variants in genes affecting lipoprotein lipase activity (e.g., LPL, APOC2, APOA5, GPIHBP1, LMF1)
    Alternate evidenceDocumented low lipoprotein lipase activity (<20% of normal)
    DocumentationMedical record documentation required to confirm genetic testing or LPL activity result
    NAFCS — diagnostic scoring
    NAFCSNorth American Familial Chylomicronemia Score (NAFCS)
    Accepted diagnostic cutoffScore ≥45 is accepted as diagnostic evidence
    Documentation
    Policy Summary
    PayerBlue Cross Blue Shield - North Carolina
    PolicyFamilial Chylomicronemia Syndrome Therapy
    Policy CodePolicy N/A
    Change TypeAdded and revised coverage for Tryngolza and Redemplo
    Effective DateApr 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with medical record documentation confirming FCS diagnosis, baseline fasting TG values, and trial/failure of conventional therapy (and for olezarsen, trial/failure of plozasiran or documented intolerance).
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaCoding, Dosing, and Clinical ThresholdsPrior Authorization, Documentation, and Provider RequirementsBackground and Condition OverviewDefinitions and Diagnostic Criteria
    Documentation Required

    Medical Record Documentation Required

    Medical record documentation is required to support the diagnosis of familial chylomicronemia syndrome (FCS), confirmation method (genetic testing, NAFCS ≥45, or ≥3 fasting TG measurements ≥880 mg/dL), prior use and inadequate response to conventional lipid-lowering therapies, adherence to a low-fat diet, inability to self-administer (and lack of caregiver), specialist involvement or consultation, and baseline and follow-up triglyceride measurements for continuation.

    • Documentation of FCS diagnostic criteria (genetic confirmation OR NAFCS ≥45 OR ≥3 fasting TG ≥880 mg/dL)
    • Documentation of trial and inadequate response (<20% TG decrease) to conventional lipid-lowering therapies (fibrates, omega-3s, statins, niacin, ezetimibe, PCSK9 inhibitors)
    • Documentation of secondary causes of hypertriglyceridemia being ruled out
    • Documentation of adherence to a low-fat diet (≤20 g fat/day)
    • Documentation of inability to self-administer and lack of caregiver/support if requesting facility administration
    • Specialist clinician involvement or consult note
    • Baseline fasting TG ≥880 mg/dL and follow-up TG demonstrating clinical response for continuation
    Denial Risk

    Requests Missing Required Documentation May Be Denied

    Requests that lack the required medical record documentation for diagnosis confirmation, trial/failure of conventional therapy, step-therapy for olezarsen, diet adherence, administration limitations, specialist involvement, or baseline/follow-up triglyceride measurements will be subject to denial.

    • Missing genetic test results, NAFCS score, or serial fasting TG records (≥3 values)
    • No documentation of trial and inadequate response to conventional lipid-lowering therapies
    • No documentation of trial or intolerance/contraindication to plozasiran when requesting olezarsen
    • No documentation of low-fat diet adherence (≤20 g/day) or lack of self-administration capability and caregiver availability
    • Absence of specialist involvement or consult
    Medical record documentation of NAFCS score is required